ライフサイエンスコーパス: retinal vein

1 c variants, and visualization of the central retinal vein.

2 nal hemorrhage than occlusion of the central retinal vein.

3 etinal hemorrhages, and dilated and tortuous retinal veins.

4 anchnic, upper-extremity, renal, ovarian, or retinal veins.

5 chemic by laser occlusion of the main branch retinal veins.

6 Central retinal vein and central retinal arterial equivalents we

7 arterial occlusion (5/16), combined central retinal vein and cilioretinal artery occlusion (4/16), a

8 erve head capillaries drain into the central retinal vein and veins of the optic nerve sheath.

9 th, elevation of the pressure in the central retinal vein, and impaired perfusion of the neurons as t

10 was used to measure P(O2) separately in the retinal veins, arteries, and capillaries and in the chor

11 the central retinal vein (CRVO) or a branch retinal vein (BRVO).

12 and hemodynamic changes in a major temporal retinal vein by laser Doppler, before and after plasmaph

13 SPCA), central retinal artery (CRA), central retinal vein (CRV), peripapillary choroid and sclera, an

14 e vision loss due to blockage of the central retinal vein (CRVO) or a branch retinal vein (BRVO).

15 h smaller central retinal artery and central retinal vein diameters.

16 In the hypoxic study, cerebral and retinal vein engorgement were correlated, and rose as th

17 al retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule

18 al retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule

19 etinal artery equivalent (CRAE), and central retinal vein equivalent (CRVE), in pediatric subjects wi

20 t veins in zone B, summarized by the central retinal vein equivalent (CRVE), the arteriole to venule

21 entral retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 17

22 Conversely, mean central retinal vein equivalent was 195.5 +/- 9.91 MU in healthy

23 Central retinal vein equivalents ranged from 228.93 +/- 21.26 mi

24 This may be the result of retinal vein impairment and hypoperfusion at the level o

25 Both the dilation of the conjunctiva and retinal veins improved.

26 were measured in the major superior temporal retinal vein in each subject by using a laser Doppler in

27 d by a robot micromanipulator, while a major retinal vein near the optic disc was occluded by argon l

28 hile 7 eyes demonstrated obvious findings of retinal vein obstruction (5 with central and 2 with hemi

29 fit, particularly for those eyes with branch retinal vein obstruction and poorer vision.

30 ondary to outflow obstruction from a central retinal vein obstruction appears to be the most common c

31 bstruction (typically central or hemicentral retinal vein obstruction) using en face optical coherenc

32 n shown to be of benefit in eyes with branch retinal vein obstruction.

33 pathy; (3) laser photocoagulation for branch retinal vein obstruction; (4) diabetic vitrectomy; (5) t

34 choroidal detachment (3.0%, n=4) and central retinal vein occlusion (0.7%, n=1).

35 ncluding pars planitis (18 eyes) and central retinal vein occlusion (2 eyes).

36 rtery occlusion (4/16), and isolated central retinal vein occlusion (4/16).

37 d by diabetic retinopathy (11 eyes), central retinal vein occlusion (6 eyes), ocular ischemic syndrom

38 urtscher's retinopathy (4 eyes, 3 patients), retinal vein occlusion (7 eyes, 7 patients), central ret

39 was associated with a 40% increased rate of retinal vein occlusion (AIRR 1.4, 95% Confidence Interva

40 betic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

41 ety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexa

42 The most common type of RVO was branch retinal vein occlusion (BRVO) (53%).

43 Early responder eyes with branched retinal vein occlusion (BRVO) and central retinal vein o

44 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high

45 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede

46 was diagnosed in 32 (27.6%) eyes, and branch retinal vein occlusion (BRVO) in 84 (72.4%) eyes.

47 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal

48 natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana

49 Branch retinal vein occlusion (BRVO) is one of the most importa

50 Branch retinal vein occlusion (BRVO) is second only to diabetic

51 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti

52 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c

53 ection for macular edema secondary to branch retinal vein occlusion (BRVO).

54 ) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

55 ative diabetic retinopathy (PDR), and branch retinal vein occlusion (BRVO).

56 ent due to macular edema secondary to branch retinal vein occlusion (BRVO).

57 retinal disease ("healthy") and with branch retinal vein occlusion (BRVO).

58 nt of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

59 ng data exists on whether central and branch retinal vein occlusion (CRVO and BRVO) are linked to sys

60 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc

61 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n

62 retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO) as a complication of persi

63 In the central retinal vein occlusion (CRVO) cohort, univariate and mul

64 ed retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) have better functional res

65 To determine the outcome of central retinal vein occlusion (CRVO) in pre-existing glaucoma a

66 Central retinal vein occlusion (CRVO) or branch retinal vein occ

67 rticipants with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

68 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

69 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus

70 Progression from a mild central retinal vein occlusion (CRVO) to a more severe CRVO was

71 Central retinal vein occlusion (CRVO) was diagnosed in 32 (27.6%

72 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec

73 ibe a patient who developed combined central retinal vein occlusion (CRVO), cilioretinal artery occlu

74 To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen

75 ers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance.

76 perfused macular edema in eyes with central retinal vein occlusion (CRVO).

77 hemiretinal vein occlusion (HRVO) or central retinal vein occlusion (CRVO).

78 aucoma, such as macular edema due to central retinal vein occlusion (CRVO).

79 r edema (ME) resolution in eyes with central retinal vein occlusion (CRVO).

80 nch retinal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).

81 CG) in eyes with the recent onset of central retinal vein occlusion (CRVO).

82 id macular oedema (CMO) secondary to central retinal vein occlusion (CRVO).

83 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori

84 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).

85 occlusion (HR: 1.13, 95% CI: 1.02-1.26) and retinal vein occlusion (HR: 1.26, 95% CI: 1.20-1.33).

86 86), glaucoma (HR: 1.40, 95% CI: 1.05-1.88), retinal vein occlusion (HR: 1.58, 95% CI: 1.23-2.03), co

87 r managing complications of ischemic central retinal vein occlusion (iCRVO).

88 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n

89 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),

90 e (ERM) (RR, 4.1, CI, 2.63-6.19), history of retinal vein occlusion (RR, 2.94, CI, 1.75-4.93), diabet

91 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or

92 oedema (DMO) (542 cases, 66.0%), followed by retinal vein occlusion (RVO) (91 cases, 13.3%).

93 Progression was associated with retinal vein occlusion (RVO) (P < .01), lower median pre

94 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi

95 he clinical unmet needs in the management of Retinal Vein Occlusion (RVO) associated Macular Edema (M

96 Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due t

97 Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive

98 is study evaluated the treatment outcomes of retinal vein occlusion (RVO) in a routine clinical pract

99 the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of

100 (RNV) and to monitor the dynamic changes of retinal vein occlusion (RVO) in living rabbits.

101 tiation in ranibizumab-treated patients with retinal vein occlusion (RVO) in the SHORE study.

102 the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients

103 Retinal vein occlusion (RVO) is a major cause of vision

104 Macular edema secondary to retinal vein occlusion (RVO) is a sight-threatening cond

105 PURPOSE OF REVIEW: Retinal vein occlusion (RVO) is a sight-threatening reti

106 Macular edema secondary to retinal vein occlusion (RVO) is an important cause of lo

107 Retinal vein occlusion (RVO) is the second most common c

108 ic, and gender composition of the cohorts of retinal vein occlusion (RVO) macular edema (ME) clinical

109 Next, efficacy was also examined in a retinal vein occlusion (RVO) model in which retinal vasc

110 es of 9 patients with either partial central retinal vein occlusion (RVO) or nonischemic RVO.

111 Investigate disparities in retinal vein occlusion (RVO) presentation and initiation

112 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c

113 ases including diabetic retinopathy (DR) and retinal vein occlusion (RVO) were recruited.

114 sented with no RVD, 20 patients (25.6%) with retinal vein occlusion (RVO), 16 patients (20.5%) with r

115 ses, including diabetic retinopathy (DR) and retinal vein occlusion (RVO), and neovascular macular di

116 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate

117 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential

118 Participants were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopathy (DR;

119 pants (n = 1063) were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopathy (DR;

120 horoidal neovascularization (CNV) and 1 with retinal vein occlusion (RVO), experienced disease quiesc

121 ve regimen for diabetic macular edema (DME), retinal vein occlusion (RVO), noninfectious uveitis macu

122 ation (AMD), diabetic macular edema (DME) or retinal vein occlusion (RVO), receiving intravitreal tre

123 Individuals were categorized as having retinal vein occlusion (RVO), retinal artery occlusion (

124 in vivo imaging measures in a mouse model of retinal vein occlusion (RVO).

125 eatment of macular edema (ME) resulting from retinal vein occlusion (RVO).

126 genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).

127 s including patients with different types of retinal vein occlusion (RVO).

128 acular edema (DME), and macular edema due to retinal vein occlusion (RVO).

129 decreased visual acuity (VA) associated with retinal vein occlusion (RVO).

130 mation may play a role in the development of retinal vein occlusion (RVO).

131 fferentiate between ischemic and nonischemic retinal vein occlusion (RVO).

132 (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

133 aturity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO).

134 r treatment of macular edema associated with retinal vein occlusion (RVO).

135 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis

136 The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi

137 the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,

138 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei

139 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini

140 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co

141 d in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to a

142 s in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).

143 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline

144 from the Study of Comparative Treatments for Retinal Vein Occlusion 2 randomized clinical trial inclu

145 d in the Study of Comparative Treatments for Retinal Vein Occlusion 2, and 88 participants randomized

146 n occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]).

147 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch

148 hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein

149 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio

150 e main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema.

151 In patients with central retinal vein occlusion and initially low visual acuity,

152 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c

153 Central and branch retinal vein occlusion are associated with increased ris

154 retinopathy, retinopathy of prematurity and retinal vein occlusion are potentially blinding conditio

155 acentral acute middle maculopathy (PAMM) and retinal vein occlusion are uncommon concurrent findings

156 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu

157 d points, AF was not associated with central retinal vein occlusion but was associated with urinary t

158 pain score) and similar to patients in other retinal vein occlusion clinical trials.

159 Central and branch retinal vein occlusion cohorts were compared with contro

160 en were associated with an increased rate of retinal vein occlusion compared to non-use, although the

161 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing

162 retinopathy, glaucoma, and branch or central retinal vein occlusion diagnosis.

163 e tomography angiography (OCTA) among branch retinal vein occlusion disease (BRVO) cases with macular

164 ve (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26).

165 and the absence of such a difference in the retinal vein occlusion group could be explained by edema

166 = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif

167 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo

168 Patients with retinal vein occlusion had higher risks of hemorrhagic s

169 to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than

170 occlusion manifesting as PAMM and incomplete retinal vein occlusion in a young male adult.

171 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA

172 Retinal vein occlusion is a common retinal vascular diso

173 Central retinal vein occlusion is a variable disease pattern.

174 Retinal ischemic damage associated with retinal vein occlusion is exacerbated by fluid extravasa

175 Retinal vein occlusion is the second most common retinal

176 ve of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).

177 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu

178 Cystoid macular edema in retinal vein occlusion occurred in relation to altered i

179 retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i

180 retrospective chart review was performed on retinal vein occlusion patients treated by three anti-va

181 The increased rate of retinal vein occlusion persisted with use of combined or

182 pathy, age-related macular degeneration, and retinal vein occlusion receiving intravitreal injections

183 hemorrhages and diagnosed as macular branch retinal vein occlusion secondary to hypertension.

184 The Collaborative Central Retinal Vein Occlusion Study has recently reported infor

185 on in the Standard Care vs Corticosteroid in Retinal Vein Occlusion Study.

186 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n

187 reference populations and patients in other retinal vein occlusion trials.

188 ORE2) and to compare with cohorts from other retinal vein occlusion trials.

189 rom 13 patients with diabetic retinopathy or retinal vein occlusion underwent both UWF-FA (Optos Silv

190 Central retinal vein occlusion was associated with an overall in

191 Branch retinal vein occlusion was associated with increased ris

192 Central retinal vein occlusion was associated with increased ris

193 Retinal vein occlusion was observed in some Cbs(+/-) mou

194 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age

195 two patients with macular edema secondary to retinal vein occlusion were enrolled in the study.

196 ar edema (ME) due to diabetic retinopathy or retinal vein occlusion were evaluated.

197 Central retinal vein occlusion with high-intensity treatment was

198 Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t

199 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and

200 h retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study.

201 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre

202 udative age-related macular degeneration, or retinal vein occlusion).

203 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were

204 omplete data; concomitant diseases including retinal vein occlusion, age-related macular degeneration

205 contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr

206 17 trials (23%) included 3757 patients with retinal vein occlusion, and 1 trial (1%) included 122 pa

207 , diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes.

208 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.

209 nal vascular diseases, diabetic retinopathy, retinal vein occlusion, and retinal artery occlusion, ma

210 such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in

211 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

212 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

213 n were the number of drug injections, having retinal vein occlusion, and under 60 years of age, while

214 In retinal vein occlusion, both ranibizumab and Ozurdex hav

215 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ

216 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN

217 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha

218 ataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland

219 ataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland

220 the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a

221 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo

222 In eyes with retinal vein occlusion, longer ME duration at the time o

223 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran

224 macular edema, macular edema associated with retinal vein occlusion, myopic choroidal neovascularizat

225 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi

226 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio

227 ulations: those with diabetic macular edema, retinal vein occlusion, or epiretinal membrane.

228 In very rare cases, acute inflammatory retinal vein occlusion, papillophlebitis or retinopathy

229 This suggests that prompt treatment for retinal vein occlusion, particularly BRVO, may be associ

230 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and

231 diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud

232 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea

233 conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis

234 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit

235 , and 4 negative control end points (central retinal vein occlusion, urinary tract infection, humeral

236 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit

237 In retinal vein occlusion, venous pressures in a segmental

238 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with

239 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal

240 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame

241 (nAMD), diabetic macular edema (DME), branch retinal vein occlusion-related macular edema (BRVO-ME),

242 related macular edema (BRVO-ME), and central retinal vein occlusion-related macular edema (CRVO-ME).

243 improving visual acuity in participants with retinal vein occlusion.

244 efield angiogram images of eyes with central retinal vein occlusion.

245 edema secondary to either central or branch retinal vein occlusion.

246 egeneration or macular edema attributable to retinal vein occlusion.

247 oliferative diabetic retinopathy and central retinal vein occlusion.

248 s can be an innovative tool in management of retinal vein occlusion.

249 n important indicator of disease severity in retinal vein occlusion.

250 eneration (AMD), diabetic macular edema, and retinal vein occlusion.

251 cular degeneration, diabetic maculopathy, or retinal vein occlusion.

252 eovascularization in the pig model of branch retinal vein occlusion.

253 acular edema, and macular edema secondary to retinal vein occlusion.

254 actor injections in macular edema associated retinal vein occlusion.

255 rosted branch angiitis complicated by branch retinal vein occlusion.

256 acular edema, and macular edema secondary to retinal vein occlusion.

257 hy (SS-OCTA) in grading macular perfusion in retinal vein occlusion.

258 morbidities such as macular degeneration and retinal vein occlusion.

259 y pre-existing diabetic retinopathy (DR) and retinal vein occlusion.

260 ncrease was observed in patients with AMD or retinal vein occlusion.

261 in patients with macular edema secondary to retinal vein occlusion.

262 the importance of systemic evaluation after retinal vein occlusion.

263 he treatment of macular edema due to central retinal vein occlusion.

264 cluded from the therapy approval studies for retinal vein occlusion.

265 and treatment of recurrent macular edema in retinal vein occlusion.

266 quantify macular edema in central and branch retinal vein occlusion.

267 ration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8 %).

268 emorrhages compatible with incomplete branch retinal vein occlusion; the right eye was normal.

269 patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein

270 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren

271 sting macular edema (ME) due to diabetes and retinal vein occlusions (RVO) make up a growing populati

272 rative diabetic retinopathy (PDR), 23.3% had retinal vein occlusions (RVO), and the remaining 15.0% s

273 story of retinal artery occlusions (RAOs) or retinal vein occlusions (RVOs) more than 6 months before

274 phase 3 Study of COmparative Treatments for REtinal Vein Occlusions 2 (SCORE2) clinical trial includ

275 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne

276 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb

277 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.

278 discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.

279 Although both retinal artery occlusions and retinal vein occlusions are associated with increased ag

280 with stroke expertise, whereas treatment of retinal vein occlusions is provided by ophthalmologists.

281 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography

282 jacent retinal arterioles than to blood from retinal vein occlusions or adjacent retinal venules, sug

283 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P

284 RETINAL VEIN OCCLUSIONS PREFERRED PRACTICE PATTERN(R) GU

285 In 20 eyes of 10 pigs, branch retinal vein occlusions were created in a standardized m

286 Retinal vein occlusions were further divided into branch

287 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.

288 eovascular age-related macular degeneration, retinal vein occlusions, or diabetic macular edema were

289 ge-related macular degeneration, and central retinal vein occlusions.

290 Direct measurement of the retinal vein pressure in the cat after acute experimenta

291 After occlusion, retinal vein pressures were measured on both sides of th

292 Upstream of the occlusion site, the retinal vein pressures were not greatly elevated, althou

293 horoidal sinus communicates with the central retinal vein, the choriocapillaris, and with large veins

294 ersus 4.78 +/- 0.37 um, p = .041), and wider retinal vein trajectories (c' = 2.48 +/- 0.84 vs 3.39 +/

295 ue plasminogen activator, 3) cannulating the retinal vein transvitreally, or 4) transecting the poste

296 inogen activator (rt-PA), 3) cannulating the retinal vein transvitreally, or 4) transecting the poste

297 ere used to create a vascular overlay of the retinal veins vs the retinal arteries to map the distrib

298 The central retinal vein was identified in six of 24 orbits.

299 Flow in retinal veins was calculated from the OCT velocity profi

300 was induced in cat retina by coagulation of retinal veins with diathermy.